- $725.99m
- $674.90m
- $183.88m
Geron Corporation reports results for the quarter ended June 30 - Earnings Summary
Geron's Q2 revenue rises on RYTELO growth
Brief: Geron Q2 EPS USD -0.02
Brief: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Geron Q1 product revenue rises 31%, net loss narrows
Brief: Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Geron Announces Appointment Of New Members To Its Board Of Directors
Geron Q4 revenue rises slightly, operating income misses estimates
Brief: Geron Corporation Provides 2026 Financial Guidance
Brief: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Walt Disney, Titan Mining, Costco Wholesale
U.S. STOCKS ON THE MOVE-Nordson, Walt Disney, Titan Mining
Geron rises on plan to cut workforce
Brief: Geron Corporation Announces Strategic Restructuring Plan To Position The Company For Long-Term Value Creation
Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales
Brief: Geron Q3 EPS USD -0.03
Brief: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Geron Corporation Announces Executive Leadership Transitions And Appointments